Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). [electronic resource]
Producer: 20200304Description: 250-258 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Capecitabine -- administration & dosage
- Drug Combinations
- Esophagogastric Junction -- drug effects
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Nivolumab -- administration & dosage
- Oxaliplatin -- administration & dosage
- Oxonic Acid -- administration & dosage
- Prognosis
- Stomach Neoplasms -- drug therapy
- Survival Rate
- Tegafur -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.